{"hands_on_practices": [{"introduction": "Effective clinical management of anogenital warts begins with accurate diagnosis. However, no diagnostic test is perfect, making it crucial for clinicians to critically evaluate the performance of the tools they use. This first practice exercise [@problem_id:4412533] challenges you to calculate the fundamental metrics of diagnostic accuracy—sensitivity, specificity, positive predictive value ($PPV$), and negative predictive value ($NPV$)—from raw clinical trial data. By working through this problem, you will solidify your understanding of how these values are derived and how they reflect a test's utility in confirming or ruling out disease.", "problem": "A venereology clinic evaluates a non-invasive index test that combines application of $5\\%$ acetic acid (acetowhitening) with handheld dermoscopy to detect external anogenital warts (condyloma acuminata). The reference standard is histopathology with Human Papillomavirus (HPV) genotype confirmation by Polymerase Chain Reaction (PCR). In a consecutive series of $N = 1000$ patients with suspected anogenital warts, the following outcomes are recorded:\n\n- Among patients with histopathologically confirmed anogenital warts (disease present), the index test is positive in $290$ and negative in $30$.\n- Among patients without histopathologically confirmed anogenital warts (disease absent), the index test is positive in $60$ and negative in $620$.\n\nUsing only the foundational definitions of conditional probability and Bayes’ theorem, derive expressions for sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) in terms of the $2 \\times 2$ classification counts. Then compute their numerical values from the data above. Report each value as a decimal (not a percentage), rounded to four significant figures. The final answer must list the four values in the order: sensitivity, specificity, PPV, NPV.", "solution": "The problem requires the derivation and calculation of four key metrics for a diagnostic test: sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). We begin by formalizing the problem using the language of probability theory and constructing a contingency table from the provided data.\n\nLet $D$ be the event that a patient has histopathologically confirmed anogenital warts (disease present), and let $\\bar{D}$ be the complementary event that the patient does not have the disease (disease absent).\nLet $T$ be the event that the index test is positive, and let $\\bar{T}$ be the complementary event that the index test is negative.\n\nThe provided data can be classified into four categories:\n- True Positives ($TP$): The number of patients with the disease who test positive. This corresponds to the event $D \\cap T$.\n- False Negatives ($FN$): The number of patients with the disease who test negative. This corresponds to the event $D \\cap \\bar{T}$.\n- False Positives ($FP$): The number of patients without the disease who test positive. This corresponds to the event $\\bar{D} \\cap T$.\n- True Negatives ($TN$): The number of patients without the disease who test negative. This corresponds to the event $\\bar{D} \\cap \\bar{T}$.\n\nFrom the problem statement:\n- Among patients with disease: $TP = 290$ and $FN = 30$.\n- Among patients without disease: $FP = 60$ and $TN = 620$.\n\nThe total number of patients with the disease is $n(D) = TP + FN = 290 + 30 = 320$.\nThe total number of patients without the disease is $n(\\bar{D}) = FP + TN = 60 + 620 = 680$.\nThe total number of patients with a positive test is $n(T) = TP + FP = 290 + 60 = 350$.\nThe total number of patients with a negative test is $n(\\bar{T}) = FN + TN = 30 + 620 = 650$.\nThe total number of patients in the study is $N = TP + FN + FP + TN = 290 + 30 + 60 + 620 = 1000$.\n\nThe data can be summarized in a $2 \\times 2$ contingency table:\n\n|                 | Disease Present ($D$) | Disease Absent ($\\bar{D}$) | Row Total     |\n|-----------------|-----------------------|----------------------------|---------------|\n| Test Positive ($T$) | $TP = 290$            | $FP = 60$                  | $350$         |\n| Test Negative ($\\bar{T}$) | $FN = 30$             | $TN = 620$                 | $650$         |\n| Column Total    | $320$                 | $680$                      | $N=1000$      |\n\nNow, we derive the expressions for the four metrics based on conditional probability and Bayes' theorem. Probabilities are estimated from the sample counts.\n\n1.  **Sensitivity (True Positive Rate)**\n    Sensitivity is the probability of a positive test result, given that the patient has the disease. It is defined as a conditional probability:\n    $$ \\text{Sensitivity} = P(T | D) = \\frac{P(T \\cap D)}{P(D)} $$\n    In terms of the counts from our sample, this is estimated as:\n    $$ \\text{Sensitivity} = \\frac{n(T \\cap D)}{n(D)} = \\frac{TP}{TP + FN} $$\n\n2.  **Specificity (True Negative Rate)**\n    Specificity is the probability of a negative test result, given that the patient does not have the disease. It is also a conditional probability:\n    $$ \\text{Specificity} = P(\\bar{T} | \\bar{D}) = \\frac{P(\\bar{T} \\cap \\bar{D})}{P(\\bar{D})} $$\n    In terms of counts:\n    $$ \\text{Specificity} = \\frac{n(\\bar{T} \\cap \\bar{D})}{n(\\bar{D})} = \\frac{TN}{TN + FP} $$\n\n3.  **Positive Predictive Value (PPV)**\n    PPV is the probability that a patient has the disease, given that the test result is positive. It is the conditional probability $P(D | T)$. We use Bayes' theorem for its derivation:\n    $$ \\text{PPV} = P(D | T) = \\frac{P(T | D) P(D)}{P(T)} $$\n    The denominator, $P(T)$, is the total probability of a positive test, which can be expanded using the law of total probability:\n    $$ P(T) = P(T \\cap D) + P(T \\cap \\bar{D}) = P(T | D) P(D) + P(T | \\bar{D}) P(\\bar{D}) $$\n    Substituting the frequency estimates for these probabilities:\n    $P(D) \\approx \\frac{n(D)}{N}$, $P(\\bar{D}) \\approx \\frac{n(\\bar{D})}{N}$, $P(T|D) \\approx \\frac{n(T \\cap D)}{n(D)}$, $P(T|\\bar{D}) \\approx \\frac{n(T \\cap \\bar{D})}{n(\\bar{D})}$.\n    $$ \\text{PPV} \\approx \\frac{\\left( \\frac{n(T \\cap D)}{n(D)} \\right) \\left( \\frac{n(D)}{N} \\right)}{\\left( \\frac{n(T \\cap D)}{n(D)} \\right) \\left( \\frac{n(D)}{N} \\right) + \\left( \\frac{n(T \\cap \\bar{D})}{n(\\bar{D})} \\right) \\left( \\frac{n(\\bar{D})}{N} \\right)} = \\frac{\\frac{n(T \\cap D)}{N}}{\\frac{n(T \\cap D)}{N} + \\frac{n(T \\cap \\bar{D})}{N}} = \\frac{n(T \\cap D)}{n(T \\cap D) + n(T \\cap \\bar{D})} $$\n    This simplifies to the more direct count-based expression:\n    $$ \\text{PPV} = \\frac{TP}{TP + FP} $$\n\n4.  **Negative Predictive Value (NPV)**\n    NPV is the probability that a patient does not have the disease, given that the test result is negative. It is the conditional probability $P(\\bar{D} | \\bar{T})$. Again, using Bayes' theorem:\n    $$ \\text{NPV} = P(\\bar{D} | \\bar{T}) = \\frac{P(\\bar{T} | \\bar{D}) P(\\bar{D})}{P(\\bar{T})} $$\n    The denominator, $P(\\bar{T})$, is the total probability of a negative test:\n    $$ P(\\bar{T}) = P(\\bar{T} \\cap D) + P(\\bar{T} \\cap \\bar{D}) = P(\\bar{T} | D) P(D) + P(\\bar{T} | \\bar{D}) P(\\bar{D}) $$\n    Using a similar substitution with frequency estimates as for PPV, we obtain:\n    $$ \\text{NPV} \\approx \\frac{n(\\bar{T} \\cap \\bar{D})}{n(\\bar{T} \\cap D) + n(\\bar{T} \\cap \\bar{D})} $$\n    This simplifies to the count-based expression:\n    $$ \\text{NPV} = \\frac{TN}{TN + FN} $$\n\nNow, we compute the numerical values using the given data, rounding to four significant figures.\n\n**Sensitivity Calculation:**\n$$ \\text{Sensitivity} = \\frac{TP}{TP + FN} = \\frac{290}{290 + 30} = \\frac{290}{320} = 0.90625 $$\nRounded to four significant figures, Sensitivity $= 0.9063$.\n\n**Specificity Calculation:**\n$$ \\text{Specificity} = \\frac{TN}{TN + FP} = \\frac{620}{620 + 60} = \\frac{620}{680} \\approx 0.9117647... $$\nRounded to four significant figures, Specificity $= 0.9118$.\n\n**Positive Predictive Value Calculation:**\n$$ \\text{PPV} = \\frac{TP}{TP + FP} = \\frac{290}{290 + 60} = \\frac{290}{350} \\approx 0.8285714... $$\nRounded to four significant figures, PPV $= 0.8286$.\n\n**Negative Predictive Value Calculation:**\n$$ \\text{NPV} = \\frac{TN}{TN + FN} = \\frac{620}{620 + 30} = \\frac{620}{650} \\approx 0.9538461... $$\nRounded to four significant figures, NPV $= 0.9538$.\n\nThe final results for the four metrics are:\n- Sensitivity: $0.9063$\n- Specificity: $0.9118$\n- Positive Predictive Value (PPV): $0.8286$\n- Negative Predictive Value (NPV): $0.9538$", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.9063  0.9118  0.8286  0.9538\n\\end{pmatrix}\n}\n$$", "id": "4412533"}, {"introduction": "Expertise in venereology extends beyond interpreting a single test result to synthesizing a wide array of clinical and pathological data. This next exercise [@problem_id:4412569] presents a detailed clinical vignette, complete with a histopathology report, challenging you to navigate the diagnostic and management pathway for a patient with anogenital lesions. This practice is designed to sharpen your ability to correlate clinical presentation with microscopic findings and apply current treatment guidelines to formulate a holistic and appropriate care plan.", "problem": "A patient aged $29$ years, who is immunocompetent and not pregnant, presents with multiple, exophytic, skin-colored papules clustered on the vulvar vestibule and perineum. The lesions have a verrucous, cauliflower-like surface and have slowly enlarged over $4$ months. She uses condoms inconsistently and has no systemic symptoms. Baseline laboratory testing is negative for Human Immunodeficiency Virus (HIV) and syphilis. Cervical cancer screening $1$ year ago was normal. Because the lesions were atypically confluent and to establish a definitive diagnosis, a shave biopsy of one representative papule was performed.\n\nHistopathologic report:\n- Marked acanthosis with elongation of rete ridges.\n- Papillomatosis and parakeratosis.\n- Numerous koilocytes in the upper spinous and superficial layers, with perinuclear halos and nuclear irregularity.\n- No stromal invasion; basement membrane remains intact.\n- Mitoses confined to the basal and parabasal layers without atypical forms.\n\nBased solely on the above histopathologic features integrated with the epidemiology and pathobiology of Human Papillomavirus (HPV) infection, identify the most accurate diagnosis and the most appropriate next management step for this patient.\n\nA. Condyloma acuminatum (anogenital warts) due to low-risk HPV types $6/11$; offer either patient-applied imiquimod $5\\%$ cream $3$ times per week for up to $16$ weeks or provider-administered destructive therapy such as cryotherapy or trichloroacetic acid, with counseling on transmission, recurrence, screening for other Sexually Transmitted Infections (STIs), and consideration of HPV vaccination if not previously immunized.\n\nB. Vulvar high-grade squamous intraepithelial lesion (HSIL; bowenoid papulosis) associated with HPV types $16/18$; proceed to wide local excision with oncologic margins and referral to gynecologic oncology.\n\nC. Invasive squamous cell carcinoma of the vulva; perform radical excision with sentinel lymph node mapping and cross-sectional imaging for staging.\n\nD. Molluscum contagiosum; perform curettage of all lesions and reassure that no further evaluation is necessary beyond routine care.\n\nE. Condyloma acuminatum; initiate podofilox (podophyllotoxin) in pregnancy as first-line therapy and defer STI counseling because partner treatment is mandatory for cure.", "solution": "The problem statement will first be validated for scientific soundness, completeness, and objectivity before a solution is attempted.\n\n### Step 1: Extract Givens\n\n-   **Patient Profile**: Age $29$ years, immunocompetent, not pregnant.\n-   **Clinical Presentation**: Multiple, exophytic, skin-colored papules clustered on the vulvar vestibule and perineum. The surface is described as verrucous and cauliflower-like. The lesions have shown slow enlargement over a period of $4$ months.\n-   **Risk Factors**: Inconsistent condom use.\n-   **Symptoms**: No systemic symptoms.\n-   **Laboratory/Screening Data**: Human Immunodeficiency Virus (HIV) negative, syphilis negative. Cervical cancer screening $1$ year ago was normal.\n-   **Procedure**: A shave biopsy of a representative papule was performed.\n-   **Histopathologic Findings**:\n    1.  Marked acanthosis with elongation of rete ridges.\n    2.  Papillomatosis and parakeratosis.\n    3.  Numerous koilocytes in the upper spinous and superficial layers, characterized by perinuclear halos and nuclear irregularity.\n    4.  No stromal invasion; the basement membrane is intact.\n    5.  Mitoses are confined to the basal and parabasal layers, and no atypical forms are present.\n-   **Question**: Identify the most accurate diagnosis and the most appropriate next management step based on the integration of histopathology, epidemiology, and pathobiology.\n\n### Step 2: Validate Using Extracted Givens\n\n-   **Scientific Grounding**: The problem describes a classic case of anogenital warts. The clinical description (exophytic, verrucous, cauliflower-like papules in the anogenital area) and the patient's risk factor (inconsistent condom use) are typical for condyloma acuminatum. The histopathologic findings are pathognomonic for Human Papillomavirus (HPV) infection: acanthosis (thickening of the epidermis), papillomatosis (undulation of the epidermis), and koilocytosis (vacuolated keratinocytes with irregular nuclei) are the hallmark features. The mention of an intact basement membrane and mitoses confined to the basal layer correctly points towards a benign process, distinguishing it from invasive carcinoma or high-grade dysplasia. The entire scenario is scientifically and medically accurate.\n-   **Well-Posedness**: The problem provides a complete set of data—patient demographics, clinical findings, and definitive histopathology—sufficient to establish a diagnosis and formulate a management plan. A unique, standard-of-care-based answer is determinable.\n-   **Objectivity**: The problem uses precise, standard medical terminology (e.g., \"acanthosis,\" \"koilocytes,\" \"papillomatosis\") and is free from subjective or ambiguous language.\n\n### Step 3: Verdict and Action\n\nThe problem statement is valid. It is scientifically sound, well-posed, and objective, presenting a realistic clinical scenario in dermatology and venereology. I will now proceed with the derivation of the solution and evaluation of the options.\n\n### Derivation of Diagnosis and Management Plan\n\n1.  **Diagnosis**: The combination of clinical and histopathological findings leads to a definitive diagnosis.\n    -   The clinical appearance of \"exophytic, verrucous, cauliflower-like\" papules in the anogenital region is quintessential for **Condyloma Acuminatum** (anogenital warts).\n    -   The histology confirms this diagnosis. Koilocytes are cells that have undergone cytopathic changes due to HPV infection and are the histologic sine qua non of this condition. The other features—acanthosis, papillomatosis, and parakeratosis—are supportive findings for a verrucous lesion caused by HPV.\n    -   The absence of stromal invasion and the confinement of non-atypical mitoses to the basal layer rule out invasive squamous cell carcinoma and high-grade squamous intraepithelial lesion (HSIL), respectively.\n    -   Epidemiologically, over $90\\%$ of anogenital warts are caused by **low-risk HPV types $6$ and $11$**. High-risk types (e.g., $16, 18$) are the primary cause of cervical cancer and other anogenital malignancies but are less commonly associated with classic exophytic condylomata.\n\n2.  **Management**: The management strategy must be based on standard evidence-based guidelines (e.g., from the CDC) for a non-pregnant, immunocompetent patient.\n    -   **Treatment of Lesions**: The goal is the removal of symptomatic warts. There is no single superior treatment. Options are categorized as patient-applied or provider-administered.\n        -   **Patient-applied**: Imiquimod $5\\%$ cream, podofilox $0.5\\%$ solution/gel, or sinecatechins $15\\%$ ointment.\n        -   **Provider-administered**: Cryotherapy with liquid nitrogen, trichloroacetic acid (TCA) or bichloroacetic acid (BCA) application, or surgical removal (e.g., shave excision, curettage, electrosurgery).\n        -   Offering the patient a choice between these categories is considered best practice.\n    -   **Comprehensive Care**: Management extends beyond lesion removal.\n        -   **Counseling**: The patient must be counseled that treatments address the visible warts but may not eradicate the underlying HPV infection, so recurrences are common. Transmission (primarily sexual) and prevention (condoms reduce but do not eliminate risk) must be discussed.\n        -   **STI Screening**: Diagnosis of any STI warrants screening for others. While HIV and syphilis are negative, screening for chlamydia and gonorrhea is indicated.\n        -   **HPV Vaccination**: The patient is $29$ years old. The 9-valent HPV vaccine is approved for individuals up to age $45$, with shared clinical decision-making recommended for those aged $27-45$. Vaccination would be beneficial as it protects against other HPV types in the vaccine (including high-risk types $16, 18$) she may not have been exposed to.\n\n### Evaluation of Options\n\n-   **A. Condyloma acuminatum (anogenital warts) due to low-risk HPV types $6/11$; offer either patient-applied imiquimod $5\\%$ cream $3$ times per week for up to $16$ weeks or provider-administered destructive therapy such as cryotherapy or trichloroacetic acid, with counseling on transmission, recurrence, screening for other Sexually Transmitted Infections (STIs), and consideration of HPV vaccination if not previously immunized.**\n    -   **Diagnosis**: Correct. The diagnosis and likely etiology are accurately stated.\n    -   **Management**: Correct. Presents a standard choice between a valid patient-applied therapy (imiquimod) and valid provider-administered therapies (cryotherapy, TCA). The specific regimen for imiquimod is also correct.\n    -   **Counseling/Ancillary Care**: Correct. It includes all essential components of comprehensive care.\n    -   **Verdict**: **Correct**.\n\n-   **B. Vulvar high-grade squamous intraepithelial lesion (HSIL; bowenoid papulosis) associated with HPV types $16/18$; proceed to wide local excision with oncologic margins and referral to gynecologic oncology.**\n    -   **Diagnosis**: Incorrect. The histopathology, specifically the confinement of normal mitoses to the basal layer and the absence of significant nuclear atypia throughout the epithelium, is inconsistent with HSIL.\n    -   **Management**: Incorrect. This is overly aggressive treatment for the diagnosed condition.\n    -   **Verdict**: **Incorrect**.\n\n-   **C. Invasive squamous cell carcinoma of the vulva; perform radical excision with sentinel lymph node mapping and cross-sectional imaging for staging.**\n    -   **Diagnosis**: Incorrect. The histopathology report explicitly states \"No stromal invasion; basement membrane remains intact,\" which by definition rules out invasive carcinoma.\n    -   **Management**: Incorrect. This is the treatment for invasive cancer and is entirely inappropriate.\n    -   **Verdict**: **Incorrect**.\n\n-   **D. Molluscum contagiosum; perform curettage of all lesions and reassure that no further evaluation is necessary beyond routine care.**\n    -   **Diagnosis**: Incorrect. The clinical description (cauliflower-like) and histopathology (koilocytes) do not match molluscum contagiosum, which presents as umbilicated papules and shows Henderson-Patterson bodies on histology.\n    -   **Management**: Incorrect. The diagnosis is wrong, and dismissing the need for STI counseling for a newly diagnosed sexually transmitted infection is substandard care.\n    -   **Verdict**: **Incorrect**.\n\n-   **E. Condyloma acuminatum; initiate podofilox (podophyllotoxin) in pregnancy as first-line therapy and defer STI counseling because partner treatment is mandatory for cure.**\n    -   **Diagnosis**: The diagnosis of \"Condyloma acuminatum\" is correct.\n    -   **Management  Counseling**: This section contains multiple critical errors. The patient is stated to be **not pregnant**. Furthermore, podofilox is **contraindicated** in pregnancy. STI counseling should never be deferred. Finally, partner treatment is not considered mandatory for cure of the patient's lesions, and this statement is misleading.\n    -   **Verdict**: **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "4412569"}, {"introduction": "In modern medicine, choosing a treatment involves balancing clinical effectiveness with economic considerations. When multiple effective options exist for anogenital warts, how do we systematically evaluate which provides the best value? This final practice exercise [@problem_id:4412626] introduces you to the principles of health economics by asking you to perform a cost-effectiveness analysis. By calculating the incremental cost per additional successful outcome, you will gain practical experience in a quantitative method used to inform clinical guidelines and healthcare policy.", "problem": "A sexual health clinic is conducting a short-horizon economic evaluation of two first-line treatments for external anogenital warts (condyloma acuminata) over a time horizon of $12$ weeks, using the healthcare provider perspective and direct medical costs only, with no discounting over this time frame. The two strategies are topical imiquimod cream versus clinic-based cryotherapy. The clinic assumes the following resource utilization and unit costs per patient over $12$ weeks:\n\n- Imiquimod strategy:\n  - Medication (imiquimod $5\\%$ cream): total course cost $=\\$170$.\n  - Clinic visits: $2$ visits at $\\$70$ each.\n  - Symptomatic management for local irritation (emollient and counseling time): $\\$10$ per patient.\n  - Probability of complete wart clearance by week $12$: $0.42$.\n\n- Cryotherapy strategy:\n  - Treatment sessions: $5$ sessions at $\\$90$ each.\n  - Post-procedure dressings and supplies: $5$ packs at $\\$10$ each.\n  - Probability of complete wart clearance by week $12$: $0.58$.\n\nAssume that all patients follow the specified resource use schedule for their assigned strategy, and that the probability of complete clearance represents the effectiveness measure per patient over the $12$-week horizon. Under a standard cost-effectiveness framework, define the incremental cost per additional clearance of cryotherapy relative to imiquimod as the ratio of the difference in mean per-patient costs to the difference in mean per-patient probabilities of complete clearance over $12$ weeks.\n\nCompute this incremental cost per additional clearance for cryotherapy relative to imiquimod. Round your answer to four significant figures. Express the final value in United States dollars (USD) per additional clearance. Do not include the unit in your final numeric answer.", "solution": "The problem requires the calculation of the incremental cost per additional clearance for cryotherapy relative to imiquimod. This is a standard calculation in health economics, formally known as the Incremental Cost-Effectiveness Ratio ($ICER$). The analysis is set over a time horizon of $12$ weeks, using only direct medical costs from the healthcare provider's perspective, without discounting.\n\nFirst, we must calculate the total mean cost per patient for each treatment strategy. Let $C_{IMI}$ and $C_{CRYO}$ represent the mean costs for the imiquimod and cryotherapy strategies, respectively.\n\nFor the imiquimod strategy, the total cost $C_{IMI}$ is the sum of the medication cost, the cost of clinic visits, and the cost for symptomatic management. The given values are:\n- Medication cost: $\\$170$.\n- Clinic visits: $2$ visits at a cost of $\\$70$ per visit.\n- Symptomatic management: $\\$10$.\n\nThe total mean cost for the imiquimod strategy is:\n$$C_{IMI} = 170 + (2 \\times 70) + 10$$\n$$C_{IMI} = 170 + 140 + 10 = 320$$\nThus, the mean cost per patient for the imiquimod strategy is $\\$320$.\n\nFor the cryotherapy strategy, the total cost $C_{CRYO}$ is the sum of the cost for treatment sessions and the cost of post-procedure supplies. The given values are:\n- Treatment sessions: $5$ sessions at a cost of $\\$90$ per session.\n- Post-procedure supplies: $5$ packs at a cost of $\\$10$ per pack.\n\nThe total mean cost for the cryotherapy strategy is:\n$$C_{CRYO} = (5 \\times 90) + (5 \\times 10)$$\n$$C_{CRYO} = 450 + 50 = 500$$\nThus, the mean cost per patient for the cryotherapy strategy is $\\$500$.\n\nNext, we identify the effectiveness for each strategy. The effectiveness is defined as the probability of complete wart clearance by week $12$. Let $E_{IMI}$ and $E_{CRYO}$ represent the effectiveness for the imiquimod and cryotherapy strategies, respectively.\n- Probability of clearance for imiquimod, $E_{IMI} = 0.42$.\n- Probability of clearance for cryotherapy, $E_{CRYO} = 0.58$.\n\nThe incremental cost per additional clearance ($ICER$) for cryotherapy relative to imiquimod is calculated as the ratio of the difference in costs ($\\Delta C$) to the difference in effectiveness ($\\Delta E$).\n$$ICER = \\frac{\\Delta C}{\\Delta E} = \\frac{C_{CRYO} - C_{IMI}}{E_{CRYO} - E_{IMI}}$$\n\nWe compute the incremental cost, $\\Delta C$:\n$$\\Delta C = C_{CRYO} - C_{IMI} = 500 - 320 = 180$$\nThe incremental cost is $\\$180$.\n\nWe compute the incremental effectiveness, $\\Delta E$:\n$$\\Delta E = E_{CRYO} - E_{IMI} = 0.58 - 0.42 = 0.16$$\nThe incremental effectiveness is $0.16$.\n\nFinally, we substitute these differences into the $ICER$ formula to find the incremental cost per additional clearance:\n$$ICER = \\frac{180}{0.16} = 1125$$\n\nThe result is an incremental cost of $\\$1125$ to achieve one additional case of complete clearance when choosing cryotherapy over imiquimod. The problem specifies that the answer should be rounded to four significant figures. The value $1125$ already consists of four significant figures ($1$, $1$, $2$, and $5$), so no rounding is necessary.", "answer": "$$\\boxed{1125}$$", "id": "4412626"}]}